A Nature Communications publication presents a therapeutic breakthrough in glioblastoma by utilizing polyclonal tumor-reactive lymphocytes expanded from tumor-infiltrating lymphocytes (TILs). This personalized immunotherapy harnesses the patient's immune cells, offering a promising new avenue against this aggressive brain cancer resistant to conventional treatments.